Study aid only. Verify against current guidelines, primary literature, staging manuals, and prescribing information before clinical use.

← All algorithms  ·  Related notes →

Chronic Lymphocytic Leukemia — Treatment

First-line Second-line SECOND-LINE CLL needing treatment Frontline · del(17p)/TP53 Frontline · no del(17p) Relapsed / refractory Continuous Covalent BTK inhibitor ELEVATE-TN ↗ Fixed-duration Venetoclax + obinutuzumab CLL14 ↗ Continuous BTK inhibitor ELEVATE-TN ↗ Fixed-duration Venetoclax + obinutuzumab CLL14 ↗ Fixed-duration Venetoclax + rituximab MURANO ↗ Switch class Pirtobrutinib BRUIN ↗ Cellular CD19 CAR-T (liso-cel) TRANSCEND CLL ↗